



# ASPIRE Collaborative Meeting

July 12th 2024

---

---

A scenic view of a sandy dune overlooking a large body of water under a blue sky with white clouds. People are seen walking on the dune.

**THANK YOU!**

# Post Meeting Information on our website

- Presentation slides, notes, and recordings
- CME Information



[About](#) [Sites](#) [Research](#) [Quality](#) [Tools](#) [Downloads](#) [News/Events](#)



Please note, the Performance Review information will not be recorded










# Featured Member May and June

[MORE INFO](#)



**Julio Benitez, MD**  
MyMichigan Health-Midland Medical Center



# Upcoming Events



# ACQR Retreat

September 13, 2024  
Henry Center, Lansing



# MPOG Annual Retreat

October 18, 2024  
Philadelphia



# **2025 Events**

**MSQC/ASPIRE Collaborative Meeting**

April 11, 2025

**ASPIRE Collaborative Meeting**

July 18, 2025

**ACQR Retreat**

September 12, 2025

**MPOG Retreat**


October 10, 2025



# **Recruitment 2024 - 2025**



- 45 sites now across the state
- Anticipate more sites will be added in the next year or two
- Acquisitions + new interested sites)






# **QIRT Updates**


# Phase 1, 2, and 3: Performance Improvements

- Increasing amounts of data processed resulted in visualizations in the QI Reporting tool that were loading slowly.
- We agreed to work on the Hospital and Provider Comparison Graphs first
- We completely changed the back end of how we obtain and store performance data.
- Obtaining the last 2 years of data should be very quick




# Improvements to PUL 01 Measure Summary Screen

- Available with departmental level access
- Informational breakdown of PEEP and Tidal Volume
- Enabled us to retire PUL-02
- Introduced concepts of "MPOG tips" and new visualization types that we can re-use





# Updated Breakdown by location graph



# Updated Result Reasons

Case

Result Reasons



**Result**

Passed

Flagged

Excluded

Excluded

Excluded

Excluded

**Total**

**Reason**

High glucose treated

High glucose not treated

Outpatient case ≤ 30 minutes

No high glucose values

High glucose value(s) resulted within 90 minutes of measure end OR provider not signed in within 90 minutes after high glucose value

ASA 5 or 6

**Case Count**

7

7

160

139

9

1

**323**

# New filters

- Locations - based on your updates to the location mapping
- Case attributes - added new filters based on existing phenotypes
- Demographics - expanding use of patient attributes. Help view performance through disparities of care lens

## Additional Filters

+ Location

### ▼ Case Attributes

Admission Status +

Anesthesia Technique +

Emergency Status +

Non-OR Anesthesia +

Surgical Service +

### ▼ Demographics

Age +

Sex +

Race +


BMI +

# Provider Measure Summary


- New provider performance trend over time compared to other like providers in their department
- New benchmark graph
- New flagged cases widget
- New result reason visualizations

## SUS-06-Peds: Low Fresh Gas Flow, Pediatric Induction [More Info](#)

Percentage of pediatric cases < 18 years old with a mean fresh gas flow (FGF) equal to or less than a weight-based threshold during the induction phase of anesthesia.




**Provider Comparison** [Provider Comparison](#)  
The provider comparison graph reveals performance differences among similar providers at your institution. Please note that the specifics of each measure (particularly the volume of cases in each measure) and provider factors can lead to outliers. These outliers might exaggerate the actual performance difference. Please interpret these graphs with these considerations in mind.



# Health system details

- View all hospitals within a health system
- Benchmarked across Michigan and nationally







# Coming very soon - Site Selected Dashboard

View measures on emails alongside other measures of interest

"Star" measures of departmental interest not on emails





**Provider  
Feedback Study  
Update**

# Progress to date

**Aim 1: Systematically capture recipient requirements and preferences for precision feedback messages**

- 35 provider interviews, 3 design iterations of prototype messages
- Preference survey under completed

**Aim 2: Implement and assess a demonstration precision feedback software service**

- Software development, performance testing, and integration completed

**Aim 3: Assess the effects of a precision feedback service**


- Pilot study completed
- Cluster-randomized trial ongoing

Dear Alex,

You may have an opportunity to improve your performance on measure [NMB-01: Train of Four Taken](#), which measures the percentage of cases with a documented Train of Four (TOF) after last dose of non-depolarizing neuromuscular blocker.

More information about the rationale for the measure and how it is calculated [is available here](#).

Below is your complete MPOG quality performance report...



[BP-01: Low MAP Prevention < 55](#)

[BP-02: Avoiding Medication Errors](#)

	You, 100% (43 / 43)
	All Other Attendings, 100% (7497 / 7528)
	You, 89% (41 / 46)


The logo consists of a large white circle with a dark blue border, centered on a dark blue background. Inside the circle, the text "ASPIRE Performance Improvement" is written in a bold, dark blue, sans-serif font. "ASPIRE" is on the top line, "Performance" is on the second line, and "Improvement" is on the third line.

**ASPIRE**  
**Performance**  
**Improvement**




# ASPIRE Performance Improvement

## SUS-01: Mean Fresh Gas Flow, $\leq 3$ L/min




# ASPIRE Performance Improvement

## PUL-01: Median Tidal Volume, <10 ml/kg




# ASPIRE Performance Improvement Hyperglycemia Management & Treatment




# ASPIRE Performance Improvement TEMP-03: Perioperative Hypothermia

\*Inverse Reporting (% flagged cases)



# ASPIRE Performance Improvement TRAN-02: Overtransfusion

\*Inverse Reporting (% flagged cases)







**Transfusion  
Toolkit Update**

# Existing Toolkits



## Acute Kidney Injury (AKI)

[Click Here](#)



## Acute Respiratory Complications

[Click Here](#)



## Perioperative Transfusion Stewardship

[Click Here](#)



## Postoperative Nausea and Vomiting (PONV)

[Click Here](#)




## Surgical Site Infection

[Click Here](#)



## Sustainability Toolkit

[Click Here](#)



**Pay-for-  
Performance  
(P4P) Scorecard -  
2025**

## 2025 P4P Scorecard: Cohorts 1-7

No changes to site participation requirements for 2025.



2025 Anesthesiology Quality Improvement and Reporting Exchange (ASPIRE) Collaborative Quality Initiative Performance Index Scorecard Cohorts 1 - 7 Measurement Period: 01/01/2025 - 12/31/2025			
Measure #	Weight	Measure Description	Points
1	10%	<b>Collaborative Meeting Participation: ASPIRE Quality Champion and Anesthesiology Clinical Quality Reviewer (ACQR) combined attendance at meetings. Three total meetings with six opportunities for attendance.</b>	
		6 / 6 Meetings	10
		5 / 6 Meetings	5
		4 or Less Meetings	0
2	5%	<b>Attend ASPIRE Quality Committee e-meetings: ASPIRE Quality Champion or ACQR attendance across six meetings.</b>	
		5 - 6 / 6 Meetings	5
		4 or Less Meetings	0
3	5%	<b>ACQR/ASPIRE Quality Champion perform data validation, case validation and submit data by the 3rd Wednesday of each month for January - November and by the 2nd Wednesday of the month for December. Data must be of high quality upon submission with &gt;90% of all high priority and required diagnostics marked as 'Data Accurately Represented.'</b>	
		10 - 12 / 12 Months	5
		9 or Less Months	0
4	10%	<b>Site Based Quality Meetings: Sites to hold an onsite in-person or virtual meeting following the three ASPIRE Collaborative meetings to discuss the data and plans for quality improvement at their site.</b>	
		3 Meetings	10
		2 Meetings	5
		1 Meeting	0


Global Warming Footprint  
SUS-02 Performance  $\geq$  55%

Update Race & Ethnicity  
Variable Mapping

New data type: Sexual orientation,  
sex, and gender identity data  
added to extract & mapped

Site Directed Measure

5	25%	Global Warming Footprint (SUS 02): Percentage of cases where carbon dioxide equivalents (CO <sub>2</sub> eq) normalized by hour for cases receiving halogenated agents and/or nitrous oxide is less than CO <sub>2</sub> eq of 2% sevoflurane at 2L FGF = 2.83 kg CO <sub>2</sub> /hr or the Total CO <sub>2</sub> eq is less than 2.83 kg CO <sub>2</sub> for the maintenance period of anesthesia. (Cumulative score January 1, 2025 through December 31, 2025)	
		Performance is $\geq$ 55%	25
		Performance is $\geq$ 45%	15
		Performance is $\geq$ 40%	10
		Performance is < 40%	0
6	10%	<b>Race &amp; Ethnicity: Race and ethnicity variables mapped to updated MPOG concepts to align with new OMB standards.</b>	
		All race & ethnicity variables mapped to updated MPOG concepts by December 31, 2025.	10
		Race & ethnicity variable mapping not updated to correspond to MPOG concepts by December 31, 2025.	0
7	10%	<b>Sexual Orientation, Sex, &amp; Gender Identity: All sexual orientation and gender identity variables in electronic health record extracted and mapped to an accepted MPOG concept to align with updated OMB standards.</b>	
		All sexual orientation, sex, and gender identity fields extracted, mapped, and submitted to MPOG by December 31, 2025.	10
		All sexual orientation, sex, and gender identity fields extracted but not yet mapped and/or submitted to MPOG by December 31, 2025.	5
		All sexual Orientation, sex, and gender identity variables not yet included in the MPOG extract.	0
8	25%	<b>Site Directed Measure: Site chooses a measure they are performing below threshold for a process measure or above threshold for an outcome measure to improve for the year.</b> (Cumulative score January 1, 2025 through December 31, 2025)	
		Performance is $\geq$ 90% for process or $\leq$ 5% for outcome, or shows $\geq$ 15% improvement (absolute)	25
		Performance is $\geq$ 85% for process or $\leq$ 10% for outcome, or shows $\geq$ 10% improvement (absolute)	15
		Performance is $\geq$ 80% for process or $\leq$ 20% for outcome, or shows $\geq$ 5% improvement (absolute)	10
		Performance is < 80% for process or > 20% for outcome, or shows < 5% improvement (absolute)	0



**Value Based  
Reimbursement  
(VBR)  
Measures -  
2026**

# 2026 VBR Measures

Performance Period: 10/1/2024 - 9/30/2025		
GLU-11	Hyperglycemia Treatment	Target: $\geq 55\%$
PONV-05	PONV Prophylaxis, Adults	Target: $\geq 60\%$
SUS-02	Global Warming Footprint, Maintenance	Target: $\geq 50\%$

Participating specialist is eligible if they have at least 2 years of data in MPOG.

Performance calculated at hospital level – providers practicing at more than one hospital are assigned to the hospital where they performed the most cases

### **Increase in fee schedule:**

3% – aggregate hospital performance met for 2 / 3 measures

5% – aggregate hospital performance met for 3 / 3 measures



# 2026 VBR Smoking Cessation Measures

Performance Period: 10/1/2024 - 9/30/2025		
SMOK-01	Smoking Tobacco Status Documentation	Target: ≥80%
SMOK-02	Smoking Tobacco Cessation Intervention	Target: ≥50%

Participating specialist is eligible if they have at least 2 years of data in MPOG.

## **Increase in fee schedule:**

- Additional 2% – aggregate hospital performance met for 2 / 2 measures



**Thank You!**